PDCD1 and lung carcinoma: According to the instruction of the application of PD-1 mAbs in clinic, the approved PD-1 mAbs have a half-life ranging from 5 days to 20 days or more, it is recommended for lung cancer patients with intravenous drip of PD-1 mAb (1, 3 or 10 mg/kg) every two weeks or three weeks (Lee et al., 2018; Mo et al., 2018; Patnaik et al., 2015; Wrangle et al., 2018).